Tiziana Life Sciences PLC Total Voting Rights and StemPrintER Update (6123R)
01 Julio 2020 - 1:00AM
UK Regulatory
TIDMTILS
RNS Number : 6123R
Tiziana Life Sciences PLC
01 July 2020
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Total Voting Rights and StemPrintER Demerger Update
London, New York, 1 July 2020 - Tiziana Life Sciences plc
(Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and
UK biotechnology company that focuses on the discovery and
development of novel molecules to treat human disease in oncology
and immunology, today announces that plans to effect the demerger
of StemPrintER from the Group are continuing to be progressed and
it is now expected that a circular will now be sent to shareholders
shortly after the Annual General Meeting to be held on 16 July
2020.
ATM Issues during June 2020
During the calendar month of June, the Company issued a total of
2,343,445 ordinary shares under the Company's ATM sales agreement
announced on 15 April 2020 to meet sales of a total of 468,689 ADSs
under the ATM sales agreement, totaling gross proceeds of
$2,785,003 in the month of June 2020. Those ordinary shares were
admitted to trading on AIM under the Company's "US ADS ATM Placing
Scheme" block listing.
Total Voting Rights
In conformity with DTR 5.6.1, the Company notifies that as at
the date of this announcement, it has a single class of shares in
issue being Ordinary Shares, the total number of Ordinary Shares in
issue will be 166,409,013. There are no Ordinary Shares held in
treasury. Each Ordinary Share entitles the holder to a single vote
at general meetings of the Company.
The figure of 166,409,013 Ordinary Shares may be used by
shareholders (and others with notification obligations) as the
denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
to their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA &
UK AIMS: TILS) biotechnology company that focuses on the discovery
and development of novel molecules to treat human diseases in
oncology, inflammation and infectious diseases. In addition to
milciclib, the Company will be shortly initiating phase 2 studies
with orally administered foralumab for Crohn's Disease and nasally
administered foralumab for progressive multiple sclerosis.
Foralumab is the only fully human anti-CD3 monoclonal antibody
(mAb) in clinical development in the world. This phase II compound
has potential application in a wide range of autoimmune and
inflammatory diseases, such as Crohn's Disease, multiple sclerosis,
type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is
desirable. The company is accelerating development of
anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for
treatment of COVID-19 patients.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further enquiries:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner +44 (0)20 7213 0880
Optiva Securities Limited (Broker)
Robert Emmet + 44 (0)20 3981 4173
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKKKBKOBKDBAN
(END) Dow Jones Newswires
July 01, 2020 02:00 ET (06:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Tiziana Life Sciences (LSE:TILS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024